Greed Is a Hell of a Drug
On Sept. 24, the Californian multinational Gilead Sciences announced it would lower the price of lenacapavir — a highly effective pre-exposure prophylaxis (PrEP) drug that prevents HIV transmission — from more than $28,000 per annual regimen, to $40, starting in 2027. UNAIDS Director Winnie Byanyima described Gilead’s price drop asContinue Reading












